BiomX (PHGE) Receives a Rating Update from a Top Analyst
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BiomX (PHGE), with a price target of $20.00. The company’s shares closed last Thursday at $6.05.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 37.5% and a 60.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on BiomX is a Strong Buy with an average price target of $25.00, which is a 313.9% upside from current levels. In a report issued on May 27, Ladenburg Thalmann & Co. also assigned a Buy rating to the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.05 and a one-year low of $4.65. Currently, BiomX has an average volume of 21.01K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
Read More on PHGE: